Mumbai: Cipla has announced that the United States Food and Drug Administration (USFDA) has classified the inspection at the manufacturing facility of Medispray Laboratories Private Limited, a ...

Cipla’s shares have surged 6% since saying last week it received final approval from the US Food and Drug Administration for its generic version of Bristol Myers Squibb’s Abraxane, a cancer ...

In compliance with the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 we hereby notify that the Operations and Administrative Committee of the ...

After a 13 per cent decline from its peak of March 2025 over the past three weeks, Cipla has fallen into oversold territory. However, recent trading activity suggests a potential shift in trend.

The Western Cape High Court has interdicted Cipla Medpro from infringing its competitors' trademark. The Western Cape High Court has interdicted Cipla Medpro (Pty) Ltd from passing off its ...

Nomura India maintains 'Buy' rating on Cipla with Rs 1,780 target by March 2026. Cipla's Goa site receives USFDA approval for gAbraxane, paving way for FY26 launch. Launch expected in 1HFY26 ...

Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment drug. The company has received the final approval from the US Food and Drug ...

Cipla is currently trading at Rs 1417.00, reflecting a decline of 1.09% today, with a 7-day exponential moving average of Rs 1479.82. Cipla's stock is currently valued at Rs 1419.15, reflecting a 0.94 ...

Technical charts hint that pharma shares such as Cipla, Lupin, Sun Pharma, Zydus Lifesciences and Gland Pharma could slide up to 23% as Trump tariff threat on pharma import looms.

Indian pharmaceutical stocks experienced a downturn following Donald Trump's renewed threat to impose tariffs on pharmaceutical imports. The Nifty Pharma index fell by 1.7%, with major companies ...

Indian Pharmaceutical companies, from Sun Pharma Ltd., to Lupin Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Ltd., Gland Pharma Ltd., fell up to 5% on Wednesday, April 9, after US President ...

Cipla is currently valued at Rs 1431.0, with a gain of 3.35% today, while its one-month returns stand at a decrease of 1.88%. The Indian oral rehydration solution market, valued at Rs 1000 crore, is ...